Finanzen von MacroGenics Inc (MGNX)MGNXMacroGenics Inc

Evaluating the bottom line, MacroGenics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -42.19%, while the net margin is -212.12%. These profitability ratios, combined with a Return on Equity (ROE) of -225.85%, provide a clear picture of how effectively MGNX converts its operational activities into shareholder value.

In the context of the broader market, MGNX competes directly with industry leaders such as PDSB and STRO. With a market capitalization of $141.41M, it holds a significant position in the sector. When comparing efficiency, MGNX's gross margin of 100.00% stands against PDSB's N/A and STRO's 100.00%. Such benchmarking helps identify whether MacroGenics Inc is trading at a premium or discount relative to its financial performance.

The company has shown volatility in revenue, with a significant drop in Q2 2025 revenue to $6.87 million, but it rebounded to $32.83 million in Q2 2026. The gross margin has fluctuated, peaking at 100% in Q2 2025 and Q2 2026, but the overall financial performance remains inconsistent with recent net income swings from losses to profits.